Bodybuilding (Primary Practical Application): Individuals who chronically use anabolic-androgenic steroids (AAS) or oral C17- alkylated agents face risks such as left ventricular hypertrophy, impaired diastolic function, elevated blood pressure, and shifts in inflammatory markers (e.g., hs-CRP). In this demographic, Cardiogen is utilized for "on-cycle" or "post-cycle" cardiovascular support. A typical regimen involves a 10 mg subcutaneous injection every 3–4 days for a duration of 3–4 weeks, or intermittent use throughout longer cycles. The objective is not an acute enhancement of athletic performance, but rather the mitigation of myocardial fibrosis and the long-term progression of cardiovascular aging markers.
General Cardiovascular Health Maintenance: Within the broader context of anti-aging and cardiovascular prevention, this peptide is employed in quarterly maintenance protocols for individuals over the age of 40. Administered either orally or subcutaneously, it aims to support signaling balance within cardiomyocytes and normalize the ratio of fibroblasts to cardiomyocytes.
Research Use: As a laboratory research tool, it is used to investigate short peptide–DNA interactions, the regulation of fibroblast activity, and signaling pathways within cardiomyocytes.
Molecular Level: The AEDR tetrapeptide sequence contains two acidic residues-glutamic acid (Glu) and aspartic acid (Asp)-as well as the guanidino group of arginine (Arg). Fluorescence-labeling studies indicate that short peptides of the Khavinson family can penetrate the cytoplasm, nucleus, and nucleolus, and bind to specific DNA oligonucleotide sequences in vitro. While Cardiogen does not exhibit significant binding to single-stranded DNA, it demonstrates a marked fluorescence-quenching effect on double-stranded DNA and methylated DNA–ethidium bromide complexes, suggesting a weak interaction with double-stranded DNA.
Cellular Level: The primary targets are fibroblasts and cardiomyocytes. In vitro and animal data indicate that AEDR can modulate fibroblast proliferation and secretory phenotypes, normalize the senescence-associated secretory phenotype (SASP), and limit excessive proliferation and fibrotic potential. In myocardial tissue, it promotes the synthesis of structural proteins within cardiomyocytes (such as actin, tubulin, vimentin, and lamins). Furthermore, in rat models of myocardial injury, it has been shown to reduce mortality and accelerate functional recovery.
Pharmacokinetic Profile: As an unmodified short peptide, Cardiogen has a half-life in plasma and tissues measured in minutes, as it is rapidly hydrolyzed by peptidases. Its biological effects do not depend on sustained plasma concentrations; rather, they persist through the reprogramming of gene expression triggered by brief exposure. This explains why a low dosing frequency-once every 3–4 days-is sufficient to maintain its effects throughout a cycle.
(I) Counteracting AAS-Related Myocardial Remodeling
Long-term use of anabolic-androgenic steroids (AAS) is associated with increased left ventricular wall thickness, impaired diastolic function, and a predisposition toward myocardial fibrosis. Theoretically, Cardiogen's regulation of fibroblasts can limit the accumulation of pro-fibrotic signaling, helping to maintain homeostasis in the myocardial interstitial ratio. For bodybuilders, the primary objective of incorporating this peptide into a cycle is to slow the progression of structural myocardial changes, rather than to reverse existing damage.
The systemic inflammatory burden resulting from high-intensity training and the use of performance-enhancing drugs can accelerate "inflammaging" (inflammation-driven aging) within the cardiovascular system. In the context of bodybuilding, Cardiogen's ability to normalize the senescence-associated secretory phenotype (SASP)-as observed in cardiovascular models-may potentially exert a beneficial influence on long-term trends in systemic inflammatory markers, such as high-sensitivity C-reactive protein (hs-CRP).
There are no reported interactions between Cardiogen and AAS, SARMs, growth hormone-axis peptides, statins, ACE inhibitors/ARBs, or PDE5 inhibitors. It can be used in an alternating daily regimen with vascular endothelium-targeting peptides (such as Vesugen) to create a synergistic support protocol covering both the myocardium and the vascular endothelium.
There is no need for a loading phase or a tapering period; the target dose is used from the start, and administration can simply cease at the end of the cycle. Monitoring is not based on drug concentration levels, but rather on benchmarks such as resting heart rate, home blood pressure readings, lipid profiles, and high-sensitivity C-reactive protein (hs-CRP)-comparing post-cycle values against baseline data. Evaluation cycles are measured in months, not days.
If administered via injection, fasting is not strictly required. However, because the assessment of Cardiogen relies on the stability of cardiovascular indicators, high caffeine intake (from coffee, tea, cola, guarana, etc.) can interfere with the interpretation of baseline resting heart rate and blood pressure; it is recommended to avoid such intake for 12 hours prior to blood draws or physiological measurements. A high-sodium diet can also compromise the validity of blood pressure monitoring, so sodium intake should remain relatively consistent throughout the cycle.
Cardiogen does not inhibit endogenous pathways and carries no risk of receptor desensitization; therefore, it does not conflict with conventional cardiovascular medications at a pharmacokinetic level. Two points, however, should be noted: First, if you are using anticoagulants or antiplatelet agents, you must personally assess the risk of bleeding at the subcutaneous injection site (applying firm pressure to the site is generally sufficient; no systemic drug-drug interactions have been reported). Second, there is no human safety data available for pregnant or breastfeeding individuals, or for those under the age of 18; use is strictly contraindicated in these groups. For the bodybuilding community, the most critical safety baseline is that Cardiogen cannot replace standard medical treatment for diagnosed cardiovascular conditions. Users should complete a baseline electrocardiogram (ECG) and echocardiogram before beginning, and undergo follow-up evaluations upon completion of the cycle.
We are the original manufacturer, not a third-party reseller. We operate our own peptide synthesis and purification production lines. The entire process for Cardiogen (AEDR)-from condensation, cleavage, and purification to lyophilization (freeze-drying)-is carried out in our own facilities, with no involvement from intermediaries, repackagers, or resellers. This ensures that the synthesis records, purification profiles, and quality control data for every batch are fully traceable to the source of production.
Professional-grade production equipment ensures sequence precision. As a short peptide consisting of only four amino acids, the challenge with AEDR lies not in its length, but in maintaining sequence integrity and batch-to-batch consistency. We utilize Solid-Phase Peptide Synthesis (SPPS) combined with preparative High-Performance Liquid Chromatography (HPLC) purification. Each batch undergoes rigorous verification via both HPLC and mass spectrometry (MS) to confirm the correct molecular weight and sequence, minimizing the presence of truncated or incomplete peptide sequences.
Consistent purity and batch-to-batch reproducibility. Cardiogen meets a purity standard of >=98.0% (by HPLC). Each shipment includes a Certificate of Analysis (COA) detailing the HPLC chromatogram, mass spectrometry confirmation, moisture content, and acetate content. For bodybuilders and athletes who use the product periodically over the long term, fluctuations in purity between batches can lead to unpredictable dosages of the active substance-a variable we have eliminated through our standardized purification process.
Reliable supply to support needs from research to large-scale production. Our production capacity ranges from milligram-scale quantities for research to hundred-gram-scale bulk supplies. The lyophilized powder is packaged in vacuum-sealed aluminum foil bags or glass vials, with a shelf life of 24 months when stored at -20℃. For individuals or teams requiring consistent use over multiple cycles, a stable supply ensures continuity, eliminating the uncertainties that arise when switching between different sources.
Comprehensive after-sales support. Every batch comes with complete technical documentation (COA, MSDS, and analytical methods). Should you have any questions regarding purity or sequence, we support third-party testing and verification. As the manufacturer, we take full responsibility for the product itself, rather than considering our obligation fulfilled merely upon shipment.
Q: Where is your production facility located? A: Our products originate from Shenzhen, China.
A: The minimum order quantity is 10 bottles/units.
A: For items in stock, shipment will be arranged within 24 hours.
A: Our standard purity is 99%.
A: We offer shipping via FedEx, DHL, UPS, and postal services.
A: Approximately 10–15 days.
Q: Can you provide a COA (Certificate of Analysis) and an HPLC (High-Performance Liquid Chromatography) test report?
A: Yes, these can be provided; all products undergo professional testing before shipment.
A: Yes, OEM services are available, subject to meeting the minimum order quantity (MOQ) requirements.
Q: How do you handle after-sales issues?
A: If a quality issue attributable to our production is confirmed after the customer receives the shipment, we offer free replacement or a refund. We operate with a pragmatic and responsible approach-we address all concerns proactively and properly, without evasion or shifting blame, to fully protect our customers' interests.
A: We accept bank transfers, Bitcoin, TransferWise, and Xoom.
étiquette à chaud: cardiogen 20 mg/vial – high-purity research-grade peptide – chinese supplier, China cardiogen 20 mg/vial – high-purity research-grade peptide – chinese supplier manufacturers, suppliers, factory
